Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See more on REPL stock here.

Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...

Replimune Group beat estimated earnings by 7.000000000000001%, reporting an EPS of $-0.77 versus an estimate of $-0.83. Revenue was down $0 from the same period last year. The company missed on EPS by ...

Market researchers expect strong growth in AI infrastructure in 2026, while rising storage prices will dampen demand for end devices. Faster, bigger, smarter — the efforts of manufacturers and ...

Vercel has launched "react-best-practices," an open-source repository featuring 40+ performance optimization rules for React and Next.js apps. Tailored for AI coding agents yet valuable for developers ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Run PostgreSQL in Python — No Setup Required Love PostgreSQL as a database, but hate having to provision it for your Python programs? The pgserver library spins up a no-maintenance, self-contained ...